The iFuse implant system is intended for use in patients with sacroiliac joint dysfunction. It consists of a sterile, cannulated triangular titanium implant with a porous surface, and a surgical instrument system for implantation.
Status In progress
Process MT
ID number 355

Provisional Schedule

Expected publication 02 October 2018

Project Team

Project lead Kimberley Carter

Email enquiries


External assessment group CEDAR
Manufacturers SI-Bone
Manufacturers of related technologies not included in scope Medtronic
Others Boston Scientific
  Department for Health and Social Care (DHSC)
  Healthcare Improvement Scotland (HIS)
  Johnson & Johnson Medical Ltd
  Medicines and Healthcare Products Regulatory Agency (MHRA)
  NHS England (NHSE)
Professional groups Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Devices for Dignity
  Medical Technology Group
  Royal College of Pathologists
  The British In Vitro Diagnostics Association (BIVDA)


Key events during the development of the guidance:

Date Update
21 September 2018 The final quality assurance step (resolution) ensures that NICE acts fairly by offering consultees the opportunity to review a pre-publication copy of the final guidance and consultation responses. This stage has now been completed and no requests for resolution were received on this technology.
20 August 2018 Resolution
20 July 2018 Committee meeting: 2
01 June 2018 - 29 June 2018 Draft guidance
20 April 2018 Committee meeting: 1
01 November 2017 Scope published
02 October 2017 Stakeholder registration opens

For further information on how we develop guidance, please see our page about NICE medical technologies guidance